Back

Single-cell characterisation of the hematopoietic bone marrow interactome in health and disease

Ennis, S.; Conforte, A.; O'Reilly, E.; Cichocka, T.; Pal Dhami, S.; Nicholson, P.; Krebs, P.; O Broin, P.; Szegezdi, E.

2022-09-15 cancer biology
10.1101/2022.05.13.491790 bioRxiv
Show abstract

1The bone marrow (BM) is a complex microenvironment and the primary site of hematopoiesis, coordinating the production of billions of blood cells every day. Despite the essential role of the hematopoietic niche in maintaining hemostasis and its relevance to hematopoietic diseases, many aspects of this environment remain poorly characterised due to experimental hurdles. Here we present a high-resolution characterisation of the niche in health and acute myeloid leukemia (AML) by establishing a comprehensive single-cell gene expression database of nearly 340,000 BM constituent cells encompassing all disease stages (healthy BM, AML at diagnosis, remission and relapse). We characterised the cell type composition of the BM and found that the proportions of both myeloid and lymphoid lineage cell types are significantly altered in AML. We also determined broadscale dysregulation of gene expression in almost all BM cell types upon establishment of AML, indicating that the entire niche is disrupted by the disease. Given the importance of interactions between hematopoietic cells and their microenvironment in regulating their function and properties, we determined all possible ligand-receptor interactions between hematopoietic stem and progenitor cells (HSPC) and every other BM constituent cell type. This analysis revealed a remarkable expansion of HSPC interactions in AML involving multiple BM constituent cells that can drive dysregulated HSPC-cell adhesion, immunosuppression and enhanced cytokine signalling. In particular, we found that interactions involving TGFB1 become widespread in AML and present evidence that these interactions can drive AML cell quiescence in vitro, thus highlighting TGFB1 signalling as a potential target for increasing drug sensitivity and preventing relapse. Our results shed light on potential mechanisms of enhanced competitiveness of AML HSPCs and an overall skewed microenvironment that fosters AML growth.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Leukemia
42 papers in training set
Top 0.1%
9.9%
2
Cancers
213 papers in training set
Top 0.5%
8.0%
3
Blood Advances
62 papers in training set
Top 0.3%
6.8%
4
Experimental Hematology
11 papers in training set
Top 0.1%
6.8%
5
PLOS ONE
5266 papers in training set
Top 32%
4.4%
6
Oncogenesis
12 papers in training set
Top 0.1%
4.1%
7
Haematologica
25 papers in training set
Top 0.2%
3.2%
8
Scientific Reports
3612 papers in training set
Top 39%
2.7%
9
eLife
5828 papers in training set
Top 38%
2.7%
10
Blood
74 papers in training set
Top 0.6%
2.4%
50% of probability mass above
11
HemaSphere
16 papers in training set
Top 0.1%
2.4%
12
Frontiers in Immunology
638 papers in training set
Top 5%
2.4%
13
Cells
249 papers in training set
Top 2%
2.1%
14
International Journal of Molecular Sciences
494 papers in training set
Top 6%
2.1%
15
Experimental Cell Research
28 papers in training set
Top 0.2%
1.7%
16
Computers in Biology and Medicine
128 papers in training set
Top 2%
1.7%
17
Clinical Epigenetics
60 papers in training set
Top 0.4%
1.5%
18
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.4%
1.5%
19
Computational and Structural Biotechnology Journal
242 papers in training set
Top 4%
1.4%
20
BMC Biology
265 papers in training set
Top 3%
1.1%
21
Journal of Leukocyte Biology
42 papers in training set
Top 0.5%
1.1%
22
Nature Communications
5641 papers in training set
Top 50%
1.1%
23
Stem Cells
31 papers in training set
Top 0.5%
1.1%
24
Clinical Cancer Research
64 papers in training set
Top 2%
1.1%
25
Molecular Cancer Research
49 papers in training set
Top 1%
1.0%
26
Biomedicines
67 papers in training set
Top 2%
1.0%
27
Oncogene
85 papers in training set
Top 2%
1.0%
28
Blood Cancer Journal
14 papers in training set
Top 0.3%
0.9%
29
EMBO Reports
263 papers in training set
Top 7%
0.9%
30
Cell Death & Disease
126 papers in training set
Top 3%
0.9%